A 117 bp fragment of the human ELA2 promoter has been characterized that can act as a minimal promoter for the expression of neutrophil elastase. Chromatin immunoprecipitation and siRNAs revealed that expression of ELA2 is regulated by the acute myeloid human leukemia 1 protein (AML1), C/EBPa, PU.1 and c-Myb transcription factors. ELA2 has also been investigated as a possible target of the leukemic fusion protein AML1-ETO resulting from the t(8;21) chromosomal translocation. AML1-ETO, like AML1, binds the ELA2 promoter in the myeloid cell lines Kasumi-1 and U937, but unexpectedly fails to significantly alter expression of ELA2. Although AML1-ETO downregulates the expression of C/EBPa, changes in C/EBPa expression do not correlate with changes in the expression of ELA2. Our observations indicate that AML1-ETO may not be a constitutive repressor of gene expression in every case in which it can associate with DNA, either on its own or in conjunction with C/EBPa. Since neither ETO nor AML1-ETO are typically expressed in hematopoietic progenitors, we hypothesize that it is the interactions between AML1-ETO and regulatory cofactors in disease-state cells that alter gene expression programs during hematopoiesis. These protein-protein interactions may not require simultaneous DNA binding by AML1-ETO for the deleterious effects of the fusion protein to be realized.
Introduction
Mutations in the transcription factors that regulate expression of genes necessary for hematopoietic development are frequently associated with a progression to human leukemia (Look, 1997) . One of the most commonly mutated genes in the acute human leukemias is the acute myeloid human leukemia 1 protein (AML1) (RUNX1, PEBP2aB, CBFA2). Mutations are a consequence of spontaneous chromosomal translocations, which create chimeric gene products whose activities are not simply the sum of the individual parts. The t(8;21) chromosomal translocation, for example, fuses the DNA-binding domain of AML1 in frame with nearly the entire EightTwenty-One protein ETO (Miyoshi et al., 1991; Erickson et al., 1992; Miyoshi et al., 1993) . The resulting AML1-ETO fusion protein is expressed in E12% of AML of the M2 subtype (Look, 1997) . AML1-ETO has been shown to interact with a number of proteins present in corepressor complexes, suggesting that AML1-ETO may act as a transcriptional repressor (Meyers et al., 1995; Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998; Westendorf et al., 1998; Amann et al., 2001; Hildebrand et al., 2001; Zhang et al., 2001; Linggi et al., 2002; Lausen et al., 2004) . However, there have been very few studies that correlate a DNA binding event by AML1-ETO at a target gene's promoter with a direct consequence on transcription (see, e.g. Linggi et al., 2002) . Since neutrophil elastase (NE) is an early marker of lineage commitment along the myeloid path, ELA2 was investigated as a possible target of AML1 and AML1-ETO (Nuchprayoon et al., 1994; Michaud et al., 2003; Peterson and Zhang, 2004) .
NE is encoded by the elastase-2 gene (ELA2), a gene that is specifically expressed in early myeloid progenitor cells (Fouret et al., 1989) . The expression of ELA2 is tightly controlled by a number of hematopoietic-specific transcription factors (Friedman, 2002) . In transient reporter gene studies, the CCAAT-enhancer binding protein (C/EBP), c-Myb and PU.1 together with the AML1 have been implicated in regulating the expression of ELA2 (Oelgeschlager et al., 1996; Nuchprayoon et al., 1997; Nuchprayoon et al., 1999) . Mutations in ELA2 are a cause of severe congenital neutropenia and cyclic neutropenia in humans (Horwitz et al., 1999; Dale et al., 2000; Ancliff et al., 2001) . ELA2 also plays a role in the development of promyelocytic leukemia by generating leukemia-promoting cleavage products of the PMLRARa fusion protein resulting from the t(15;17) chromosomal translocation Ley, 2003, 2005) .
A minimal promoter fragment that can regulate the expression of ELA2 was identified and characterized to determine which factors control expression of this gene. In the human system, as in the mouse (Nuchprayoon et al., 1994) , expression of the ELA2 gene (hELA2) is shown to be dependent on AML1 and PU.1, which cooperatively activate expression of hELA2 in conjunction with the c-Myb and C/EBPa transcription factors, respectively. These four factors are shown by chromatin immunoprecipitation (ChIP) to be resident on the minimal promoter in multiple cell lines. Although AML1-ETO can chromatin immunoprecipitate with the minimal hELA2 promoter, AML1-ETO fails to significantly alter expression levels of hELA2. The inability of AML1-ETO to modulate expression of hELA2 suggests that AML1-ETO may not always act as a repressor of gene expression when bound to DNA. An alternative view of the fusion protein considers AML1-ETO to act as a platform for regulatory cofactor exchange, altering the availability of corepressors or activators necessary for the regulation of gene expression during hematopoiesis. From this point of view, AML1-ETO could have positive and negative regulatory effects at different genes without obligation to interact with the DNA.
Results

Identification of a minimal hELA2 promoter regulated by AML1
To identify the AML1 responsive element in the human ELA2 promoter (hELA2), the upstream nucleotide sequence was inspected for potential AML1-binding sites. Two far upstream sites were found at position À1926 (TGTGGT) and at position À1742 (TGTGGT) (Figure 1a , dark boxes) and a third site identified just 70 nucleotides upstream of the transcription start site. An imperfect fourth site has also been reported at position À199 (TGCGATT) (Figure 1a ) (Li et al., 2004) . To determine the minimal AML1-responsive promoter fragment, a series hELA2 promoter luciferase constructs were prepared to define the likely binding site for AML1 (Figure 1a) .
Three cell lines were investigated: Kasumi-1, U937 and HEK 293. In Kasumi-1 and U937 cells, the expression of luciferase from five different length promoter constructs was measured (Figure 1a ). These constructs revealed that the region between À454 and À1700 can strongly stimulate expression of the reporter, but a minimally active promoter fragment required only the first 117 bp (À117/ þ 1) upstream of the transcription start site (Figure 1b ). This fragment is homologous to that previously defined for the mouse ELA2 promoter (Nuchprayoon et al., 1994; Oelgeschlager et al., 1996) . To determine where the AML1 response was localized within the promoter, several reporter constructs were cotransfected with an expression plasmid for AML1 into an AML1-deficient cell line, HEK 293. In this context, it was observed that the 117 bp fragment contained the primary region responsible for AML1-dependent gene expression ( Figure 1c) . The nucleotide sequence of the (À117/ þ 1) promoter fragment displays several potential binding sites for hematopoietic transcription factors, Figure 1 Identification of a minimal human ELA2 promoter. (a) Schematic representation of the hELA2 promoter reporter constructions screened for their ability to regulate luciferase gene expression. The location of potential AML1-binding sites is shaded black and numbered. (b) Relative activity of the hELA2 promoter constructs in Kasumi-1 and U937 cells. In all, 100 ng of expression vector was transfected into Kasumi-1 or U937 cells. The luciferase activity was measured 2 days after transfection. Values are given as relative light units (RLU) after normalization to b-galactosidase activity. (c) AML1 dependence of the hELA2 promoter constructions in HEK 293 cells. In all, 300 ng of an AML1 expression vector was cotransfected with various luciferase promoter constructs as indicated. Activity is given as fold induction relative to the observed expression levels measured in the absence of the AML1 expression vector. (d) Sequences of the minimal mouse and hELA2 promoters. Binding sites are highlighted in color and labeled. (e) Confirmation of the AML1, PU.1, C/EBP and c-Myb-binding sites by 3 to 7 nucleotide changes introduced into the (À117/ þ 1) luciferase reporter as described in Methods. Luciferase activity was given in percent relative to the activity of the wild type reporter. Three nucleotide changes were used for PU.1 ( Â PU.1) and c-Myb ( Â Myb), while six to seven nucleotide changes were used for AML1 (xAML1) and C/EBP (xC/EBP). which are homologous between the mouse and human promoters (Figure 1d) . A potential ETS factor-binding site exists between positions À93 to À84 (blue) that was shown to be occupied by either PU.1 (the Spleen Focus Forming Virus Proviral Integration Oncogene, SPI1) or GA-binding protein (GABP) in the mouse promoter (Nuchprayoon et al., 1997) . Adjacent to the PU.1/ GABP site there is an AML1 site (Figure 1c, green) , which is present in the mouse promoter, but not strictly conserved in the human sequence. A C/EBP site (red) and a c-Myb-binding site (yellow) both reside 3 0 to the AML1 site. The functionality of these sites has been demonstrated for the mouse promoter (Nuchprayoon et al., 1994; Oelgeschlager et al., 1996) . A series of mutant luciferase reporters containing the (À117/ þ 1) minimal promoter confirmed that the PU.1, AML1, C/ EBP and c-Myb sites in the human promoter are the same as those previously characterized in the mouse (Figure 1e ).
Cooperation of transcription factors on the human ELA2 (À117/ þ 1) construct To examine the relative activity of the transcription factors within the (À117/ þ 1) promoter, expression vectors were cotransfected with the (À117/ þ 1) reporter gene into HEK 293 cells. To avoid expression at saturating levels, the luciferase activity was measured after 24 h. AML1 induces the activity of the (À117/ þ 1) promoter construct in a dose-dependent manner, causing a sixfold increase of activity at the highest level of overexpression ( Figure 2a ). Ectopic expression of C/ EPBa activates the reporter gene in a similar fashion, whereas c-Myb or PU.1 overexpression caused only a slight increase over basal level expression from the minimal promoter. The dose-response to expression of AML1, C/EBPa and PU.1 correlated with the expression levels of these proteins measured by Western blotting (Figure 2a, inset) .
To test for cooperative interactions between the transcription factors that bind (À117/ þ 1), several were transiently expressed together in HEK 293 cells. Overexpression of AML1 with C/EBPa or AML1 with PU.1 revealed total expression levels of hELA2 approximately equal to the sum of the values observed with either of these factors alone (Figure 2b ), indicating that AML1 does not synergize with either C/EBPa or PU.1 on the reporter gene. By contrast, coexpression of AML1 and c-Myb was modestly synergistic and coexpression of PU.1 and C/EBPa was strongly synergistic, with a >20-fold effect at the highest level of C/EBPa expression ( Figure 2c ).
Hematopoetic transcription factors are expressed in U937 and Kasumi-1 cells To evaluate if AML1, PU.1, C/EBPa or c-Myb could potentially take part in regulation of hELA2 in cells expressing NE, the myeloid cell line U937 was tested for expression of these transcription factors. As an early marker of myelopoiesis, hELA2 may also be a target of leukemic fusion proteins resulting from spontaneous chromosomal translocation. Thus, the t(8:21) translocation cell line Kasumi-1, which constitutively expresses the AML1-ETO fusion protein, was also examined for its effect on hELA2 expression. As shown in Figure 3a , Kasumi-1 cells were found to express the transcription factors PU.1, AML1, C/EBPa and c-Myb by reverse transcriptase PCR (RT-PCR) and Western blot, whereas HEK 293 cells only express small amounts of AML1 and PU.1 are present on the hELA2 promoter and are necessary for its expression ChIP was performed to verify the occupancy of the hELA2 promoter by the transcription factors found to regulate its expression. PU.1, AML1 and C/EBPa all ChIP with the ELA2 promoter DNA fragment from U937 cells (Figure 4a ). The PCR primers used covered the sequence from À120 to þ 1, suggesting that these factors occupied the promoter DNA in the vicinity of the (À117/ þ 1) minimal promoter. When a far upstream primer pair was used, which covers nucleotides À1959 to À1707 that includes the perfect AML1 sites at À1926 and À1742, no PCR product was obtained from the ChIP (Figure 4a , lower panel). To further evaluate the role of AML1 and PU.1 in the expression of hELA2, small interfering RNAs (siRNAs) were used to knockdown expression of each of these proteins. As shown in Figure 4b , siRNA treatment decreased the expression of AML1 and PU.1 as judged by the intensity of the signal in a Western blot. Similarly, the level of RNA was decreased for AML1 and PU.1 upon siRNA treatment (Figure 4c ). Reduced levels of AML1 or PU.1 correlated with a loss of hELA2 expression, demonstrating that these transcription factors regulate the expression of hELA2 in a physiological context (Figure 4c ).
AML1-ETO is present at the hELA2 promoter but does not alter the expression of the gene
The human myeloid leukemia cell line Kasumi-1 expresses AML1-ETO, which could potentially interfere with AML1-dependent activation of the hELA2 promoter since hELA2 expression is dependent on AML1. Therefore, ChIP was used to determine if AML1-ETO associates with the hELA2 promoter in Kasumi-1 cells. Figure 5a demonstrates that the ETO antibody chromatin immunoprecipitated with the hELA2 promoter DNA from Kasumi-1 cells (upper panel) but not from U937 cells (lower panel). In a Western blot, the ETO antibody used in the ChIP did not detect any of the other ETO family members (ETO-2 or MTG8R), suggesting that other ETO-like proteins are only present in low abundance in Kasumi-1 cells, if at all.
To determine the effect of AML1-ETO on hELA2 expression in Kasumi-1 cells, expression of AML1-ETO was knocked down using siRNAs as previously described (Heidenreich et al., 2003) . Figure 5b illustrates that effective reduction of AML1-ETO expression in Kasumi-1 cells can be achieved within 48 h. This results in only a modest increase in hELA2 levels (Figure 5c ). AML1-ETO has also been implicated in suppressing expression of C/EBPa (Zhang et al., 1996; Petrovick et al., 1998; Westendorf et al., 1998; Pabst et al., 2001 ), which in turn could suppress expression of hELA2 in Kasumi-1 cells. Real-time PCR and Western blot readily detect C/EBPa transcripts and protein in Kasumi-1 nuclear protein extracts (Figures 3a and 5d) , in contrast to an earlier report . siRNA knockdown of AML1-ETO modestly increased C/EBPa expression in these cells, which occurred concomitantly 
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J Lausen et al with a 13% increase in hELA2 expression. More significant effects are observed following siRNA knockdown of AML1 or PU.1 in Kasumi-1 cells, which results in near total suppression of hELA2 (Figure 5c ). siRNA knockdown of C/EBPa also effectively suppresses hELA2 gene expression, confirming the presence of C/ EBPa in these cells (see Supplementary data). Thus, although knockdown of AML1-ETO does slightly increase hELA2 expression, AML1-ETO does not appear to act as a constitutive repressor of hELA2 in Kasumi-1 cells.
Ectopic expression of AML1-ETO does not inhibit hELA2 expression
Since Kasumi-1 cells are resistant to AML1-ETO, they may have acquired secondary mutations that interfere with the repressive effects normally associated with this fusion protein (Banker et al., 1998) . Therefore, the ability of AML1-ETO to repress hELA2 expression was examined in an inducible U937 cell line that had not been previously exposed to AML1-ETO (Fliegauf et al., 2004) . Upon induction with 5 mM ponasterone A, expression of AML1-ETO is readily observed after 24-48 h (Figure 6a ). ChIP demonstrates that AML1-ETO is associated with the hELA2 promoter upon induction, whereas only AML1 is found at the promoter in the absence of ponasterone A (Figure 6b ). The fact that a pull down of promoter DNA with an anti-ETO antibody can only be achieved upon expression of AML1-ETO demonstrates that it was AML1-ETO detected from the ChIP; no other ETO-like protein(s) could have been associated with the promoter in these experiments. Two days after induction of AML1-ETO, at its peak of expression, the level of the hELA2 transcript was measured by real-time PCR. As shown in Figure 6c , ectopic expression of AML1-ETO did not significantly alter expression of the endogenous hELA2 gene in U937 cells. AML1-ETO was induced 26 times over background, whereas the relative amount of the hELA2 transcript increased 14%. This occurred concomitantly 
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with a modest decrease in C/EBPa expression. Thus, AML1-ETO did not significantly alter expression of hELA2 following induction in U937 cells, nor did the induction of AML1-ETO expression correlate with a similar change in the expression levels of C/EBPa (Figure 6c ). p21
Waf1/Cip1 was used as a control gene whose promoter is activated by AML1-ETO (Yan et al., 2004) , which is readily detected by quantitative PCR (see Supplementary data) and by microarray analysis (T Berg and M Lu¨bbert, unpublished).
Discussion
NE, encoded by the hELA2 gene, is a myeloid-specific protease that is transcriptionally regulated during early myeloid differentiation. Since it is expressed in a lineagespecific and stage-specific manner, NE, like myeloperoxidase, is a good marker of early myeloid gene expression and development. In both the mouse (Nuchprayoon et al., 1994) and human (this report), a E100 bp fragment of the promoter was shown to be minimally required to direct the expression of human ELA2 (hELA2). Functionally important binding sites for c-Myb, C/EBPa, PU.1 and AML1 are located within this minimal promoter sequence. The presence of these factors on the promoter in hELA2-expressing cells has been confirmed by ChIP and siRNA knockdown experiments in two myeloid cell lines (Figures 5 and  6 ). Downregulation of AML1 or PU.1 removed both an essential factor from the promoter and a cooperative interaction with either c-Myb or C/EBPa, suppressing the expression of hELA2. Since both AML1 and PU.1 play a central role in hELA2 expression, we expected that mutations in either of these transcription factors should influence hELA2 expression levels during early myeloid development. A particular mutation of AML1 was investigated, the chimeric gene product AML1-ETO resulting from the t(8;21) chromosomal translocation.
AML1-ETO slows, but does not block, differentiation along the myeloid lineage (Burel et al., 2001) . This effect has been attributed to the ability of AML1-ETO to interact with the corepressors and histone deacetlyases (HDACs) that might be recruited to AML1-dependent promoters and repress the expression of genes essential for differentiation (reviewed in . AML1-ETO has also been described as a constitutive repressor of gene expression in a model organism (Wildonger and Mann, 2005) . The highest level of hELA2 expression occurs in bone marrow blasts and promyelocytes during granulopoiesis (Fouret et al., 1989) , which overlaps with the expression pattern of AML1-ETO in patients harboring the t(8;21) translocation. Therefore, it was anticipated that AML1-ETO would suppress expression of hELA2. ChIP confirmed that AML1 and AML1-ETO can both bind the hELA2 promoter. While siRNA knockdown of AML1 in Kasumi-1 cells disrupts hELA2 expression, knockdown of AML1-ETO does not significantly enhance expression of hELA2 in this cell line. The same observation is made when AML1-ETO is inducibly expressed in U937 cells. Although it need not be true that AML1-ETO suppresses gene expression of every gene at which it may find a promoter-binding site, our observations are not in line with the expectation that AML1-ETO acts predominantly as a transcriptional repressor, particularly at a gene that is also regulated by C/EBPa Pabst et al., 2001) .
AML1-ETO interacts with C/EBPa and PU.1 (Zhang et al., 1996; Petrovick et al., 1998; Westendorf et al., 1998; Pabst et al., 2001) , two transcription factors implicated in the regulation of hELA2 expression. For one of these factors, C/EBPa, coassociation with AML1-ETO suppresses its own expression and that of C/EBPa target genes Pabst et al., 2001) . We observed that AML1-ETO does repress expression of C/EBPa in both Kasumi-1 and U937 cells, ChIP with an anti-ETO antibody and a C-terminal anti-AML1 antibody demonstrates that both proteins can engage the hELA2 promoter. ChIP was quantitated as described in Methods. (c) Real-time PCR analysis of hELA2 expression in the inducible U937 cell line. Following treatment with 5 mM ponasterone A, expression of AML1-ETO increases 26-fold, while no change is observed in the expression of hELA2 and only a modest reduction in C/EBPa is observed.
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J Lausen et al as had previously been described , but the level of suppression is modest. The distinction with Pabst et al. may be due to the time period over which the expression of C/EBPa was followed. Pabst et al. observed 10-30% reductions in C/EBPa expression within the first 48 h following induction of AML1-ETO expression in a Tet-off-inducible U937 cell line, similar to the level of C/EBPa suppression observed the ecdysone-induced U937 cell line used in this study. However, long-term exposure (>4 days) to AML1-ETO results in a complete loss of C/EBPa in the Tet-off system. The ecdysone-inducible U937 cells used in this study have not been followed beyond 4 days as the continuous expression of AML1-ETO results in significant cell death by day 5, thus, long-term effects of AML1-ETO on the expression of C/EBPa cannot be compared between these two studies. While Pabst et al.
reported that C/EBPa was not present in Kasumi-1 cells, we observe both mRNA and protein for C/EBPa in these cells ( Figure 3) ; we further correlate siRNA knockdown of C/EBPa with the disruption in expression of hELA2 in Kasumi-1 cells (see Supplemental data), confirming the presence of C/EBPa. The origin of this discrepancy is unknown. Transcriptional synergy between AML1 and C/EBPa is well known (Hohaus et al., 1995; Oelgeschlager et al., 1996; Zhang et al., 1996; Westendorf et al., 1998) . Under overexpression conditions, AML1-ETO and C/EBPa co-immunoprecipitate , suggesting a direct interaction between these factors is possible. Transcriptional synergy between AML1 and C/EBPa is disrupted by AML1-ETO in a transient reporter gene assay . However, transcriptional synergy need not imply an obligatory interaction between these factors in all contexts. In many cases, synergy is dependent on the relative position of factor-binding sites at a given promoter, with close proximity of the binding sites for AML1 and C/EBPa expected to give rise to synergistic activation of gene expression through direct interaction between these proteins. At hELA2, there is no transcriptional synergy between AML1 and C/EBPa (Figure 2b) , consistent with distant relationship between factor-binding sites for these proteins on the minimal promoter (Figure 1d ). Given that AML1-ETO should bind at or near the AML1 site within the hELA2 promoter (Figures 5 and  6 ), the modest effects of AML1-ETO on C/EBPa expression would not be expected to translate into a significant reduction in the expression of hELA2.
Analysis of the regulation of hELA2 gene expression suggests that the transcriptional effects of AML1-ETO are more complex than simple DNA binding and repression via recruitment of corepressors and HDACs. An alternative view considers the interaction between the fusion protein and its binding partners and how they relate to transcription from an affected gene. Perhaps the observed interaction between AML1-ETO and corepressors, HDACs or other transcription factors acts as a mechanism to remove or relocalize cofactors from the gene regulatory pool during development. From this point of view, there could be significant changes in gene expression patterns, but they may not logically reflect changes in the expression of one or a small number of genes specifically related to myeloid development. When AML1-ETO is introduced into progenitor cells that had not previously been exposed to ETO or its homologues, microarray analysis reveals a number of upregulated genes and few downregulated ones, to include genes regulating granule protein expression during early myeloid differentiation (Shimada et al., 2000) . Remarkably, the majority of affected genes are not direct targets of AML1 (Shimada et al., 2000) ; similar results are obtained from microarray analysis of the inducible U937 cells used here (T Berg and M Lu¨bbert, personal communication) . This fits well with a hypothesis that AML1-ETO can act as a platform for cofactor exchange, redistributing transcriptional cofactors from the regulatory pool, leading to disruptions in developmentally-specific gene expression patterns. Evidence for this view of AML1-ETO is mounting. AML1-ETO can, for example, interact with PU.1 and displace cofactors necessary for PU.1-mediated gene activation (Vangala et al., 2003) . A similar mechanism has been proposed for the effect of AML1-ETO on E box proteins . Indeed, AML1-ETO not only binds coregulatory factors using multiple conserved domains (Lausen et al., 2004) , AML1-ETO also oligomerizes to exert its transcriptional effects (Minucci et al., 2000; Zhang et al., 2001) . Therefore, AML1-ETO can bind multiple factors in multiple quantities to redirect regulatory proteins away from their intended targets. This is not to say that the DNA-binding domain of AML1-ETO can never serve to deliver coregulatory factors to an AML1 DNA-binding locus; rather, DNA binding may not be the primary mode by which AML1-ETO influences gene expression during development. To explore this view of AML1-ETO further, the biochemical and structural basis for the interaction between AML1-ETO and its binding partners needs to explored (reviewed in Hug and Lazar, 2004) . Since multiple binding sites for the corepressor N-CoR have been identified within ETO (Lausen et al., 2004) , which overlap with binding sites for activators of the E box family , these factors become good candidates for the analysis of biochemical mechanism(s) by which AML1-ETO alters patterns of gene expression during development.
Material and methods
Plasmids and cells
The hELA2 promoter was amplified from genomic DNA prepared from the human embryonic kidney cell line HEK 293. The different length promoter constructs were PCR amplified and cloned into the pGL3 luciferase reporter gene. All vectors used were verified by sequencing and tested for expression by Western blot using the following antibodies (Santa Cruz Biotech.), ETO: sc-29737x, PU.1: sc-352x, AML1: sc-8564x, c-Myb: sc-802 (against the S-tag of c-Myb), C/EBPa: sc-61x. Expression from the pMT-p75Myb-S construct was induced by adding 100 mM ZnCl.
Transfection into HEK 293 cells was performed with Fugene transfection reagent (Roche) following the manufacturer's instructions. Transfection of U937 was carried out with Effectenet (Qiagen). Transcriptional activity was determined 24 or 48 h after transfection, using a luciferase assay (Promega) and a tube luminometer (Berthold). Measurements of transcriptional activity were conducted from at least four independent transfections. A b-galactosidase vector was cotransfected as a transfection control. Luciferase values were normalized against b-galactosidase activity and expressed as relative light units (RLU) of the normalized luciferase activity. The total amount of transfected DNA was kept constant at 500 ng. HEK 293 (ATCC; CRL-1573) cells were maintained in Dulbecco's modified Eagles's medium (DMEM; Life technologies) supplemented with 10% fetal calf serum (Life Technologies), 50 U/ml penicillin, 50 mg/ml streptomycin, (Invitrogen). U937 and Kasumi-1 cells were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 50 U/ml penicillin, 50 mg/ml streptomycin and 2 mM L-glutamine (Invitrogen) at 371C and 5% CO 2 . The inducible AML1-ETO U937 cell line was kept with 600 mg/ml G418 (Invitrogen) and 150 mg/ml Zeocin (Invitrogen), induction was carried out with 5 mM ponasterone A (Invitrogen).
For mutation analysis of factor-binding sites, the following mutations were introduced upstream of the transcription start site in the (À117/ þ 1) reporter: xPU.1: TTT at À87 to À85; xAML1: CTCGAG at À74 to À69; xC/EBP: CTCGTTTG at À64 to À57; xMyb: TTT at À50 to À48.
ChIP assay
ChIP was performed according to the method described (Boyd et al., 1998; Liu et al., 2000) . Briefly, 10 8 cells were fixed by adding formaldehyde to a final concentration of 1% and incubated at room temperature for 10 min. After neutralization with glycine, the cells were pelleted and washed twice with cold phosphate-buffered saline . The pellet was resuspended, the nuclei isolated and sonicated until the chromatin had an average length of 600 bp. After centrifugation the supernatant was subjected to immunoprecipitation using 2 mg of antibody and 50 ml of magnetic protein-A beads (NEB; #S1425S). After extensive washing the antibody/transcription factor/DNA complex was eluted from the beads. Subsequently formaldehyde crosslinks were reversed and the proteins digested with proteinase K. The DNA was extracted with phenol/chloroform/isoamyl alcohol, washed with ethanol, resuspended in water and used for PCR using Taq polymerase (Invitrogen). Primers for the proximal ELA2 promoter were 5 0 -TGAA ATCCCCCCACCCCCG-3 RNAi and PCR Oligoribonucleotides (ORNs, Integrated-DNA-Technologies) were hybridized at a concentration of 250 mM in hybridization buffer (25 mM Tris, pH 7.5, 100 nM NaCl) by heating to 951C for 5 min and cooling down to room temperature. ORNs were 5 0 -CCUCGAAAUCGUACUGAGAAG-3 0 and 3 0 -UUG-GAGGCUUUAGCAUGACUCU-5 0 for AML1-ETO (Heidenreich et al., 2003) . ORNs for AML1 were 5 0 -CCUCGAAGACAUCGGCAGAAA-3 0 and 3 0 -UUGGAG-CUUCUGUAGCCGUCUUU-5 0 . ORNs for PU.1 were 5 0 -GUUGCTCUCCTUCCUGTTC-3 0 and 3 0 -UUCTTC-GUGTGGUTGGTCUU-5 0 . A four duplex primer set was used for C/EBPa (siGenome Smart pool reagent M00642201005, Dharmco RNA Technologies). For electroporation, 370 ml of exponentially growing cells at a concentration of 10 7 cells/ml were mixed with 1 mM siRNA. Electroporation was performed with an electrocell manipulator (ECM 830, BTX) using a rectangle electroporation protocol. The voltage setting was 150 V with a pulse length of 10 ms, 15 pulses were performed with an interval of 500 ms.
For RT-PCR RNA was extracted using the RNeasy kit (Qiagen). First-strand synthesis was carried out using 2 mg of RNA and Omniscript reverse transcriptase (Qiagen). PCR was performed using Taqt 0 . Real-time PCR was performed using the SYBRGreen PCR master mix (Applied Biosystems) and a 7900 ABI-prism sequence detection system (Applied Biosysytems). Values were normalized against GAPDH and calculated according to the manufacturer's instructions. The sequence of the real-time PCR products for ELA2 and C/EBPa were verified following gel purification by automated sequencing for RNA derived from both U937 and Kasumi-1 cells.
